- Home
- EBMT vs HURA Comparison
EBMT vs HURA Comparison
Compare EBMT & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBMT
- HURA
- Stock Information
- Founded
- EBMT 1922
- HURA 2009
- Country
- EBMT United States
- HURA United States
- Employees
- EBMT N/A
- HURA N/A
- Industry
- EBMT Major Banks
- HURA
- Sector
- EBMT Finance
- HURA
- Exchange
- EBMT Nasdaq
- HURA Nasdaq
- Market Cap
- EBMT 136.9M
- HURA 145.6M
- IPO Year
- EBMT N/A
- HURA N/A
- Fundamental
- Price
- EBMT $17.32
- HURA $2.37
- Analyst Decision
- EBMT
- HURA Strong Buy
- Analyst Count
- EBMT 0
- HURA 2
- Target Price
- EBMT N/A
- HURA $11.50
- AVG Volume (30 Days)
- EBMT 21.8K
- HURA 823.7K
- Earning Date
- EBMT 10-28-2025
- HURA 08-14-2025
- Dividend Yield
- EBMT 3.30%
- HURA N/A
- EPS Growth
- EBMT 49.06
- HURA N/A
- EPS
- EBMT 1.61
- HURA N/A
- Revenue
- EBMT $84,696,000.00
- HURA N/A
- Revenue This Year
- EBMT N/A
- HURA N/A
- Revenue Next Year
- EBMT $5.20
- HURA N/A
- P/E Ratio
- EBMT $10.91
- HURA N/A
- Revenue Growth
- EBMT 5.13
- HURA N/A
- 52 Week Low
- EBMT $14.35
- HURA $1.80
- 52 Week High
- EBMT $18.49
- HURA $8.40
- Technical
- Relative Strength Index (RSI)
- EBMT 56.12
- HURA 38.05
- Support Level
- EBMT $17.19
- HURA $2.43
- Resistance Level
- EBMT $17.99
- HURA $2.65
- Average True Range (ATR)
- EBMT 0.29
- HURA 0.18
- MACD
- EBMT 0.02
- HURA -0.07
- Stochastic Oscillator
- EBMT 48.06
- HURA 5.39
About EBMT Eagle Bancorp Montana Inc.
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.